Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health (GH) is a leader in precision oncology, pioneering non-invasive liquid biopsy tests for cancer detection and monitoring. This dedicated news hub provides investors and healthcare professionals with timely updates on the company's financial performance, clinical advancements, and strategic initiatives.
Access authoritative coverage of earnings reports, regulatory milestones, and technology innovations shaping cancer diagnostics. Our curated collection includes press releases on clinical trial results, partnership announcements, and peer-reviewed research developments directly from Guardant Health's communications.
Key updates cover FDA clearances for diagnostic assays, global commercialization efforts, and data partnerships advancing precision medicine. Stay informed about developments in molecular residual disease detection, expanded test indications, and reimbursement progress affecting healthcare adoption.
Bookmark this page for consolidated access to verified information about liquid biopsy advancements and GH's role in transforming cancer care through genomic insights. Check regularly for objective reporting on developments impacting both clinical practice and investment considerations.
Guardant Health's Shield™ blood test has received FDA approval as a primary screening option for colorectal cancer (CRC) in adults aged 45 and older at average risk. This marks a significant milestone as the first blood test approved for CRC screening that meets Medicare coverage requirements. The test offers an easy and convenient alternative to traditional screening methods, potentially improving CRC screening rates.
Key points:
- Shield demonstrated 83% sensitivity for CRC detection with 90% specificity for advanced neoplasia in the ECLIPSE study
- Over 90% adherence rate in real-world clinical settings
- Aims to address the gap in CRC screening rates, currently at 59% in the U.S.
- Potential to detect more cancers at an early stage when they are more treatable
Guardant Health (Nasdaq: GH), a leading precision oncology company, announced it will release its second quarter 2024 financial results on Wednesday, August 7, 2024, after market close.
The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET, accessible via a live webcast on the company’s website.
The webcast will be archived and available for replay after the event.
Guardant Health (NASDAQ:GH) has unveiled a major upgrade to its Guardant360 liquid biopsy test, running on the Guardant Infinity smart liquid biopsy platform. The enhanced test now covers 739 genes, a tenfold increase from its predecessor, and includes all guideline-recommended genomic biomarkers for advanced solid tumors. It offers 10 times higher sensitivity in quantifying tumor burden and can identify emerging biomarkers for precise cancer characterization.
Key features of the upgrade include:
- Broader gene panel coverage
- Analysis of both actionable and emerging biomarkers
- Results delivered in 7-10 days
- Medicare and major private payer coverage
- Improved precision in treatment strategy identification
The test's expansion aims to provide oncologists with a more comprehensive view of cancer, potentially improving patient outcomes through more targeted treatment options.
Guardant Health (NASDAQ:GH), a leader in precision oncology, has appointed Dr. Manuel Hidalgo Medina to its board of directors. Dr. Hidalgo, currently the Chief of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, brings extensive expertise in translational and clinical research, particularly in anticancer drug development. His appointment is expected to contribute significantly to Guardant Health's mission of improving patient outcomes through advanced diagnostics.
Dr. Hidalgo's impressive career includes leadership roles at Beth Israel Deaconess Medical Center, the Spanish National Cancer Research Centre, and the Kimmel Comprehensive Cancer Center. He also serves on the board of Bristol Myers Squibb, further enhancing his industry insights.
Guardant Health has launched an upgraded version of its Guardant360 TissueNext test, which now identifies 498 genes or cancer biomarkers. This expanded gene panel helps oncologists find more targeted therapies for patients with advanced cancer. Additionally, operational improvements have streamlined the workflow, reducing the time to results to less than two weeks. The test is covered by Medicare for patients with advanced solid tumors. Guardant Health aims to improve patient outcomes by providing more comprehensive gene coverage. This new test can be ordered either alone or in combination with Guardant360 CDx to support guideline-recommended genomic profiling for advanced breast and lung cancer.
Guardant Health (NASDAQ:GH), a precision oncology company, has been named to the TIME100 Most Influential Companies list. This recognition comes due to the company's impact, innovation, ambition, and success.
Guardant was included in the Innovators section, which features 20 companies from various industries. Key milestones for Guardant include achieving 500 peer-reviewed publications and delivering 500,000 patient tests.
Additionally, the FDA’s Medical Devices Advisory Committee has recommended approval for Shield™, Guardant's blood test for colorectal cancer screening. The FDA's decision is expected later this year.
Guardant Health (Nasdaq: GH) will present data from 16 studies at the 2024 ASCO Annual Meeting, May 31-June 4 in Chicago. The studies highlight the impact of Guardant's blood tests and real-world data on precision oncology and cancer screening. Key presentations include interim data from the RADIOHEAD study showing correlations between epigenomic biomarkers and immunotherapy responses across 13 cancer types.
Presentations will cover the utility of ctDNA for therapy response monitoring, the use of the GuardantINFORM clinical-genomic database to study tumor drivers and resistance, and applications of genomic and epigenomic biomarkers in cancer treatment. Featured studies focus on racial differences in genomic profiles in metastatic breast cancer and the quantification of tumor fractions using the Guardant Infinity platform.
The FDA's Molecular and Clinical Genetics Panel has strongly recommended the approval of Guardant Health's Shield™ blood test for colorectal cancer (CRC) screening in adults aged 45 and older at average risk. The panel's vote was 8 to 1 for safety, 6 to 3 for effectiveness, and 7 to 2 for benefits outweighing risks. Shield aims to improve CRC screening rates by offering a non-invasive alternative to stool-based tests. Shield demonstrated 83% sensitivity and 90% specificity for advanced neoplasia in the pivotal ECLIPSE study, aligning with existing non-invasive tests. The FDA is expected to make its decision later this year.
Guardant Health (Nasdaq: GH) announced a temporary halt in trading of its stock on Nasdaq. This pause precedes a important meeting of the FDA's Molecular and Clinical Genetics Panel, which will review the premarket approval application for Shield™, Guardant Health’s blood test aimed at screening colorectal cancer in average-risk adults. The panel meeting, starting at 9:30 a.m. ET, will provide independent expert advice to the FDA to support its decision-making process.
Guardant Health (Nasdaq: GH), a precision oncology company, announced its participation in three upcoming investor conferences.
These include the William Blair 44th Annual Growth Stock Conference in Chicago on June 4, the Jefferies Global Healthcare Conference in New York on June 5, and the Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, Florida on June 11.
Live and archived webcasts of these sessions will be available on Guardant Health's website under the 'Investors' section.
FAQ
What is the current stock price of Guardant Health (GH)?
What is the market cap of Guardant Health (GH)?
